RxDoctor Payments Data

Matthew Soberano, DO

Allergy & Immunology · Villa Rica, GANPI 1386183218

Payments from drug & device makers

$4,020in general payments, 2019–2025

Across 169 payments — averaging $23.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$1K
  • AstraZeneca$562
  • Takeda Pharmaceuticals U.S.A., Inc.$491
  • GSK$435
  • Regeneron Healthcare Solutions, Inc.$171
  • Grifols USA, LLC$131
  • plus $965 from 15 others

What the payments were for

  • Food & beverage$3,95298%
  • Education$692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,020 in reported general payments places this provider in the 40th percentile of 107 allergy & immunology providers in Georgia.

See all allergy & immunology providers in Georgia

Medicare billing

Part B allowed, 2024
$330,940
Medicare patients
259
Services billed
11,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab92$289,557
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$52,301
Dupixent PenDupilumab12$47,008
NucalaMepolizumab11$39,318
Fluticasone-SalmeterolFluticasone Propion/Salmeterol54$10,466
Advair HfaFluticasone Propion/Salmeterol16$5,623
Wixela InhubFluticasone Propion/Salmeterol30$5,429
SymbicortBudesonide/Formoterol Fumarate15$4,985
Epinephrine17$3,527
Albuterol Sulfate HfaAlbuterol Sulfate93$1,802
Azelastine Hcl69$1,741
Ipratropium Bromide28$1,619
Fluticasone Propionate93$1,094
Montelukast Sodium147$1,076
Levocetirizine Dihydrochloride67$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala$435$91,62081 claims
AstraZenecaSymbicort$562$4,98515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 107 allergy & immunology providers in Georgia.

Other allergy & immunology in Villa Rica

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →